Maxim Gorbachev
Director/Board Member at binx health, inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeffrey R. Luber | M | 57 |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 7 years |
John Michael Clarkson | M | 67 |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 19 years |
Neil Butler | M | - |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 13 years |
Karen Frances Yates | F | - |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 19 years |
Charles Huiner | M | 52 | 7 years | |
Pavel Rodyukov | M | - |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Samar Parikh | M | - |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 5 years |
Robert Ellis | M | - | 10 years | |
Sergey Beloborodov | M | - |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Vladimir Avetissian | M | - |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Emil Gafarov | M | - |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | 11 years |
Vladimir Oskarovich Gurdus | M | 59 |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | 12 years |
Yurij Udaltsov | M | - |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Keith Stauffer | M | - |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 9 years |
Inna Martin Eitan | F | - |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Ji Hua Wang | F | 61 |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 7 years |
Naomi Kelman | F | 65 |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 3 years |
Elizabeth Mora | F | 63 |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 3 years |
Leonid Melamed | M | 63 |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
David King | M | 67 |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 3 years |
Olga Yuryevna Shpichko | M | 49 |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Andrey Borisovich Malyshev | M | 64 |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | 12 years |
Nikolay Bagratovich Arutyunov | M | 60 |
Sukhoi Civil Aircraft JSC
Sukhoi Civil Aircraft JSC Aerospace & DefenseElectronic Technology Sukhoi Civil Aircraft JSC engages in the development and manufacturing of aircraft. Its activities include design and manufacturing of new models of civil aircraft, as well as certification, general project management, sales and after sales support. The company was founded on May 25, 2000 and is headquartered in Moscow, Russia. | 11 years |
Martin C. Münchbach | M | 54 |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | - |
Gail Marcus | M | 67 |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 5 years |
Joachim Rothe | M | - |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | - |
Evgeny Zaytsev | M | 56 |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Stanley Lapidus | M | 75 |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 6 years |
Jeffrey Grosklags | M | 53 |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | 2 years |
Nikolay Batulin | M | - |
RMI Partners OOO
RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
William P. Reddick | M | - |
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | 11 years |
Robert Michael Kleine | M | 70 | 4 years | |
Brian H. Dovey | M | 83 | 1 years | |
Nicole Vitullo | F | 66 |
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | 8 years |
Mark Deem | M | - | 11 years | |
Hank Plain | M | 66 | 11 years | |
Mikhail Aslanovich Pogosyan | M | 68 |
Sukhoi Civil Aircraft JSC
Sukhoi Civil Aircraft JSC Aerospace & DefenseElectronic Technology Sukhoi Civil Aircraft JSC engages in the development and manufacturing of aircraft. Its activities include design and manufacturing of new models of civil aircraft, as well as certification, general project management, sales and after sales support. The company was founded on May 25, 2000 and is headquartered in Moscow, Russia. | 2 years |
Stacey Seltzer | F | 47 | 16 years | |
Stephen Okland | M | 60 | 2 years | |
Richard Eiswirth | M | 55 |
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | - |
Hanson Gifford | M | - | 1 years | |
Barbara White | M | 73 |
UCB Pharma LLC
| 1 years |
Khalil Barrage | M | 59 |
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | 2 years |
Angela Walsh | F | 58 |
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | 4 years |
Patrick Williams | M | 51 | 1 years | |
Abel de la Rosa | M | - |
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 31 | 67.39% |
Russia | 15 | 32.61% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Maxim Gorbachev
- Personal Network